TABLE 3.
Effects of dosing with SSG or SSG-NIV on various pharmacokinetic parameters in dogsa
| Treatment (SbV dose [mg/kg]) | k12 (h−1 [10−3]) | k21 (h−1 [10−3]) | t1/2α (h) | t1/2β (h) | AUC0- ∞ (mg · h/liter) | Vc (liters/kg) | VSS (liters/kg) | CL (liters/kg · h) | MRT0-∞ (h) |
|---|---|---|---|---|---|---|---|---|---|
| SSG (40) | 0.32 ± 0.26 | 0.32 ± 0.17 | 0.24 ± 0.08 | 1.46 ± 0.51 | 241.1 ± 60.2 | 0.11 ± 0.02 | 0.25 ± 0.08 | 1.71 ± 0.04 | 1.48 ± 0.56 |
| SSG-NIV (40) | 0.15 ± 0.25 | 0.21 ± 0.17 | 0.50 ± 0.42 | 1.97 ± 1.14 | 264.4 ± 121.1 | 0.22 ± 0.1 | 0.33 ± 0.08 | 1.70 ± 0.05 | 2.19 ± 1.25 |
| SSG-NIV (20) | 0.66 ± 0.71 | 0.56 ± 0.46 | 0.20 ± 0.17 | 1.42 ± 0.15 | 154.3 ± 16.9 | 0.10 ± 0.03 | 0.21 ± 0.05 | 0.13 ± 0.01 | 1.68 ± 0.39 |
a
Dogs (n = 4/group) were given a single intravenous injection of SSG (40 mg of SbV/kg) or SSG-NIV (20 or 40 mg of SbV /kg). The values are means ± SDs. Abbreviations: k12 and k21, intercompartmental transfer rate constants; t1/2α, distribution phase half-life; t1/2β, elimination phase half-life; AUC0-∞, area under the plasma concentration-time curve projected to infinity; Vc, volume of distribution of the central compartment; VSS = steady-state volume of distribution; CL, total body clearance; MRT0-∞, mean residence time projected to infinity.